•  
  •  
  •  
  •  

2026-08-12 11:47:18

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  DrReddysLaboratories

Research

  • Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY

Stock Report

  • Dr. Reddy's Laboratories Receives U.S. FDA Approval for Rituximab Biosimilar
  • Dr. Reddy's Laboratories Reports Q1 FY27 Results: Net Profit Stands at ₹435 Crore Amid North America Softness; Sequential Earnings Surge 97%
  • Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States
  • Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India
  • Dr. Reddy's Laboratories Limited recommends final dividend of Rs. 8
  • Dr. Reddys Laboratories Ltd consolidated Q4 FY2025-26 PAT slides to Rs. 220.1 crores
  • Dr. Reddy's and Nestlé Health Science strengthens presence in diabetes & obesity nutrition space with Celevida® GLP+ launch
  • OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection
  • Dr. Reddy's Laboratories announces launch of India's first DCGI-approved Semaglutide injection 'Obeda®' for Type 2 Diabetes
  • Dr. Reddy's forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India
  • Dr Reddys Laboratories Ltd consolidated Q3 FY2025-26 PAT drops to Rs. 1209.8 crores
  • Dr. Reddy's Laboratories announces Science-Based Net Zero Climate Targets
  • Immutep and Dr. Reddy's Enter Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
  • Dr. Reddy's receives European Commission Approval for AVT03 (denosumab), a Proposed Biosimilar of Prolia® and Xgeva®
  • Dr Reddys Laboratories Ltd reports Rs. 1437.2 crores consolidated PAT in Q2FY26
  • Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for AVT03 - denosumab
  • Dr. Reddy's launches novel molecule 'Tegoprazan' in India
  • Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda®
  • USFDA completes GMP inspection at Dr. Reddy's Laboratories Ltd's API Middleburgh facility
  • Senores Pharmaceuticals acquires 14 ANDAs from Dr. Reddy's Laboratories
  • Dr. Reddy’s Laboratories Ltd Q3 FY2025 consolidated PAT higher at Rs. 1413.3 crores
  • Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
  • IPO-bound Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories
  • Dr. Reddy's Laboratories Ltd reports Rs. 1255.3 crores consolidated PAT in Q2 FY2025

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025